113 related articles for article (PubMed ID: 60119)
21. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains).
Novotný J; Handschumacher M; Haber E; Bruccoleri RE; Carlson WB; Fanning DW; Smith JA; Rose GD
Proc Natl Acad Sci U S A; 1986 Jan; 83(2):226-30. PubMed ID: 2417241
[TBL] [Abstract][Full Text] [Related]
22. Determination of cell mediated immunity against tumour associated antigens in patients of ENT.
Nowak R; Günther M; Jenssen HL; Seyfarth M; Werner H; Putzke HP
Acta Otolaryngol; 1979; 87(3-4):400-3. PubMed ID: 87106
[TBL] [Abstract][Full Text] [Related]
23. The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors.
Preece AW; Light PA
Clin Exp Immunol; 1974 Dec; 18(4):543-52. PubMed ID: 4143199
[TBL] [Abstract][Full Text] [Related]
24. Comparison between the macrophage electrophoretic mobility (MEM) and the fixed tanned erythrocyte electrophoretic mobility (FTEEM) tests in the detection of cancer.
Harlos JP; Weiss L
Int J Cancer; 1978 Apr; 21(4):413-7. PubMed ID: 78907
[TBL] [Abstract][Full Text] [Related]
25. Effects of human transfer factor on the migration of guinea-pig macrophages: is there an antigen-specific activity?
Sargent IL; Salaman MR
Immunology; 1980 Sep; 41(1):227-35. PubMed ID: 6159314
[TBL] [Abstract][Full Text] [Related]
26. Antigenic determinants of hen egg-white lysozyme in delayed hypersensitivity. I. Macrophage migration inhibition activities of lysozyme fragments.
Miyagawa N; Ashizawa T; Kashiba S; Miyagawa S; Fujio H
Biken J; 1975 Dec; 18(4):215-28. PubMed ID: 56171
[TBL] [Abstract][Full Text] [Related]
27. A common tumour specific antigen. I. Restriction in vivo to malignant neoplastic tissue.
Dickinson JP; Caspary EA; Field EJ
Br J Cancer; 1973 Feb; 27(2):99-105. PubMed ID: 4735112
[TBL] [Abstract][Full Text] [Related]
28. Antigenic determinants of hen egg-white lysozyme in delayed hypersensitivity. II. Antigenicity and immunogenicity of the N- and C-terminal peptide.
Miyagawa N; Ashizawa T; Kashiba S; Miyagawa S; Fujio H
Biken J; 1975 Dec; 18(4):229-47. PubMed ID: 56172
[TBL] [Abstract][Full Text] [Related]
29. Rapid development of a cancer-like antigen in normal tissue in vitro.
Field EJ; Hughes D; Caspary EA
Br J Cancer; 1973 Jun; 27(6):427-33. PubMed ID: 4737227
[TBL] [Abstract][Full Text] [Related]
30. A comparison between the macrophage migration inhibition test (MMI) and the leucocyte adherence inhibition test (LAI) in patients with melanoma and carcinoma of the colon.
Isbister WH
N Z Med J; 1978 Oct; 88(622):327-30. PubMed ID: 366475
[TBL] [Abstract][Full Text] [Related]
31. Multiple assay characterization of murine monoclonal antimelanoma antibodies.
Stuhlmiller GM; Borowitz MJ; Croker BP; Seigler HF
Hybridoma; 1982; 1(4):447-60. PubMed ID: 6208139
[TBL] [Abstract][Full Text] [Related]
32. T cell tolerance studied at the level of antigenic determinants. I. Latent reactivity to lysozyme peptides that lack suppressogenic epitopes can be revealed in lysozyme-tolerant mice.
Oki A; Sercarz E
J Exp Med; 1985 May; 161(5):897-911. PubMed ID: 2580937
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte sensitization in sarcoidosis.
Caspary EA; Field EJ
Br Med J; 1971 Apr; 2(5754):143-5. PubMed ID: 5581493
[TBL] [Abstract][Full Text] [Related]
34. Cancer diagnostic test of Field and Caspary: Part II. A review and interpretation of the collected data.
Kast RE
Med Hypotheses; 1980 Jan; 6(1):63-72. PubMed ID: 6155596
[TBL] [Abstract][Full Text] [Related]
35. Technical aspects of the macrophage electrophoretic mobility (MEM) test for malignant disease.
Pritchard JA; Moore JL; Sutherland WH; Joslin CA
Br J Cancer Suppl; 1973 Aug; 1():229-36. PubMed ID: 4804283
[TBL] [Abstract][Full Text] [Related]
36. Macrophage electrophoretic migration (MEM) test for lymphocyte sensitization: some practical experiences in macrophage selection.
Shenton BK; Hughes D; Field EJ
Br J Cancer Suppl; 1973 Aug; 1():215-8. PubMed ID: 4804280
[TBL] [Abstract][Full Text] [Related]
37. Evaluation and development of the macrophage electrophoretic mobility (MEM) test for malignant disease.
Pritchard JA; Moore JL; Sutherland WH; Joslin CA
Br J Cancer; 1973 Jan; 27(1):1-9. PubMed ID: 4686176
[TBL] [Abstract][Full Text] [Related]
38. Immunological activity of blood lymphocyte fractions. A study by the macrophage electrophoretic mobility method.
Minderhoud JM; Smith JK
Clin Exp Immunol; 1972 Apr; 10(4):571-9. PubMed ID: 5034245
[TBL] [Abstract][Full Text] [Related]
39. [Experiences with the macrophage electrophoresis mobility test (MEM test) in the diagnosis of malignant gynecological diseases].
Günther J
Zentralbl Bakteriol Orig B; 1975; 91(9):529-39. PubMed ID: 52961
[TBL] [Abstract][Full Text] [Related]
40. Formed blood elements in peritoneal effusion and the macrophage migration inhibition test in healthy guinea pigs and in guinea pigs with experimental allergic encephalomyelitis.
Wróblewski T
Arch Immunol Ther Exp (Warsz); 1976; 24(3):359-66. PubMed ID: 60984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
